Table 2 Description of irAEs occurring in individual patients
irAEs category | Number of patients with irAEs (%) |
|---|---|
Cutaneous | |
 Rash | 8 (8.4%) |
 Pruritus | 2 (2.1%) |
 Vitiligo | 1 (1.0%) |
Reactive cutaneous capillary endothelial proliferation | 5 (5.2%) |
Endocrine-related events | |
 Hypothyroidism | 3 (3.1%) |
 Diabetes | 1 (1.0%) |
Hepatotoxicity | |
 ALT/AST elevation | 11 (11.6%) |
Gastrointestinal toxicity | |
 Diarrhea | 3 (3.1%) |
 Gastrointestinal bleeding | 1 (1.0%) |
Immune-associated pneumonia | 7 (7.3%) |
Cardiac toxicity | 5 (5.2%) |
Hematological toxicity | |
 Leukopenia | 4 (4.2%) |
 Thrombocytopenia | 4 (4.2%) |
 Anemia | 7 (7.3%) |
Others | |
 Increased creatinine | 2 (2.1%) |
 Peripheral neuropathy | 2 (2.1%) |
 Shingles | 1 (1.0%) |
 Thromboembolism | 1 (1.0%) |
 Hippocampal inflammation | 1 (1.0%) |
 Fatigue | 3 (3.1%) |
 Amylase and lipase elevation | 1 (1.0%) |
 Oral mucositis | 1 (1.0%) |
Total patients irAEs | 53 (55.8%) |